A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Phase 1/2 Not yet recruiting 39 enrolled RinuaGene Biotechnology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

Timeline

Start: 2024-03
Primary completion: 2026-10
Completion: 2027-12

Publications

Results Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RG002	Messenger RNA (mRNA)	25 ug	Intramuscular
Subject	RG002	Messenger RNA (mRNA)	75 ug	Intramuscular
Subject	RG002	Messenger RNA (mRNA)	150 ug	Intramuscular

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Summary

Timeline

Publications

Drugs

Indications